References
- Charcot JM, Marie P. Sur uneforme particuliered’atrophie musculaire progressive, souvent familiale, debutant par les pieds et les ambs et atteignant plus tard les mains. Rev Med. 1886;6:97–138.
- Barisic N, Claeys KG, Sirotković-Skerlev M, et al. Charcot-Marie-Tooth disease: a clinico-genetic confrontation. Ann Hum Genet. 2008;72:416–441.
- Braathen GJ, Sand JC, Lobato A, et al. Genetic epidemiology of Charcot-Marie-Tooth in the general population. Eur J Neurol. 2011;18:39–48.
- Gutmann L, Shy M. Update on Charcot-Marie-Tooth disease. Curr Opin Neurol. 2015;28:462–467.
- Fridman V, Bundy B, Reilly MM, et al. CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis. J Neurol Neurosurg Psychiatry. 2015. 86:873–878.
- Bennett CL, Chance PF. Molecular pathogenesis of hereditary motor, sensory and autonomic neuropathies. Curr Opin Neurol. 2001;14:621–627.
- Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain. 1980;103:259–280.
- d'Ydewalle C, Benoy V, Van Den Bosch L. Charcot-Marie-Tooth disease: emerging mechanisms and therapies. Int J Biochem Cell Biol. 2012;44:1299–1304.
- De Jonghe P, Timmerman V, Ceuterick C, et al. The Thr124Met mutation in the peripheral myelin protein zero (MPZ) gene is associated with a clinically distinct Charcot-Marie-Tooth phenotype. Brain. 1999;122:281–290.
- Pareyson D, Scaioli V, Laurà M. Clinical and electrophysiological aspects of Charcot-Marie-Tooth disease. Neuromol Med. 2006;8:3–22.
- Miura S, Shibata H, Kida H, et al. Hereditary motor and sensory neuropathy with proximal dominancy in the lower extremities, urinary disturbance, and paroxysmal dry cough. J Neurol Sci. 2008;273:88–92.
- Nakamura N, Kawamura N, Tateishi T, et al. Predominant parasympathetic involvement in a patient with Charcot-Marie-Tooth disease caused by the MPZ Thr124Met mutation. RinshoShinkeigaku. 2009;49:582–585.
- Podnar S, Vodušek DB. Sexual dysfunction in patients with peripheral nervous system lesions. Handb Clin Neurol. 2015;130:179–202.
- Vinci P, Gargiulo P, Navarro-Cremades F. Sexuality in Charcot-Marie-Tooth disease. Eura Medicophys. 2007;43:295–296.
- Arnold A, McEntagart M, Younger DS. Psychosocial issues that face patients with Charcot-Marie-Tooth disease: the role of genetic counseling. J Genet Counsel. 2005;14:307–318.
- Gargiulo P, Vinci P, Navarro-Cremades F, et al. Sexual functioning in women with mild and severe symptoms of Charcot-Marie-Tooth disease. J Sex Med. 2013;10:1800–1806.
- Krhut J, Mazanec R, Seeman P, et al. Lower urinary tract functions in a series of Charcot-Marie-Tooth neuropathy patients. Acta Neurol Scand. 2014;129:319–324.
- Bird TD, Lipe HP, Crabtree LD. Impotence associated with the Charcot-Marie-Tooth syndrome. Eur Neurol. 1994;34:155–157.
- Crabtree L, Ont O. Charcot-Marie-Tooth disease: sex, sexuality and self-esteem. Sex Disabil. 1997;15:293–306.
- Tokuda N, Noto Y, Kitani-Morii F, et al. Parasympathetic dominant autonomic dysfunction in Charcot-Marie-Tooth disease Type 2J with the MPZ Thr124Met mutation. Intern Med. 2015;54:1919–1922.
- Cannarella R, Burgio G, La Vignera S, et al. Anejaculation in a patient with Charcot-Marie-Tooth. Asian J Androl. 2018. DOI:10.4103/aja.aja_75_17
- Sman AD, Hackett D, Fiatarone Singh M, et al. Systematic review of exercise for Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2015;20:347–362.
- Di Vincenzo C, Elzinga CD, Medeiros AC, et al. The allelic spectrum of Charcot-Marie-Tooth disease in over 17,000 individuals with neuropathy. Mol Genet Genomic Med. 2014;2:522–529.
- Sato K, Kihara K. Spinal cord segments controlling the canine vas deferens and differentiation of the primate sympathetic pathways to the vas deferens. Microsc Res Tech. 1998;42:390–397.
- Calogero AE, Burgio G, Condorelli RA, et al. Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. Aging Male. 2018;2:1–8.
- Calogero AE, Burgio G, Condorelli RA, et al. Lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction: from physiology to clinical aspects. Aging Male. 2018;1–10. DOI:10.1080/13685538.2018.1430758
- Aktas BK, Gokkaya CS, Bulut S, et al. Impact of metabolic syndrome on erectile dysfunction and lower urinary tract symptoms in benign prostatic hyperplasia patients. Aging Male. 2011;14:48–52.
- Demir O, Akgul K, Akar Z, et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male. 2009;12:29–34.
- Yassin AA, Saad F, Gooren LJ. Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia. 2008;40:259–264.
- Tsai CC, Liu CC, Huang SP, et al. The impact of irritative lower urinary tract symptoms on erectile dysfunction in aging Taiwanese males. Aging Male. 2010;13:179–183.